These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 28120466)

  • 1. New liposomal doxorubicin nanoformulation for osteosarcoma: Drug release kinetic study based on thermo and pH sensitivity.
    Haghiralsadat F; Amoabediny G; Sheikhha MH; Zandieh-Doulabi B; Naderinezhad S; Helder MN; Forouzanfar T
    Chem Biol Drug Des; 2017 Sep; 90(3):368-379. PubMed ID: 28120466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comprehensive mathematical model of drug release kinetics from nano-liposomes, derived from optimization studies of cationic PEGylated liposomal doxorubicin formulations for drug-gene delivery.
    Haghiralsadat F; Amoabediny G; Helder MN; Naderinezhad S; Sheikhha MH; Forouzanfar T; Zandieh-Doulabi B
    Artif Cells Nanomed Biotechnol; 2018 Feb; 46(1):169-177. PubMed ID: 28376641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen-functionalized liposomes grafted with glutathione-responsive sheddable chotooligosaccharides for the therapy of osteosarcoma.
    Yin X; Feng S; Chi Y; Liu J; Sun K; Guo C; Wu Z
    Drug Deliv; 2018 Nov; 25(1):900-908. PubMed ID: 29644882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EphA2 Targeted Doxorubicin-Nanoliposomes for Osteosarcoma Treatment.
    Haghiralsadat F; Amoabediny G; Naderinezhad S; Nazmi K; De Boer JP; Zandieh-Doulabi B; Forouzanfar T; Helder MN
    Pharm Res; 2017 Dec; 34(12):2891-2900. PubMed ID: 29110283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of phospholipids with high transition temperature to enhance redox-sensitive liposomal doxorubicin efficacy in colon carcinoma model.
    Mirhadi E; Askarizadeh A; Farhoudi L; Mashreghi M; Behboodifar S; Alavizadeh SH; Arabi L; Jaafari MR
    Chem Phys Lipids; 2024 Jul; 261():105396. PubMed ID: 38621603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a bone-targeted pH-sensitive liposomal formulation containing doxorubicin: physicochemical characterization, cytotoxicity, and biodistribution evaluation in a mouse model of bone metastasis.
    Ferreira Ddos S; Faria SD; Lopes SC; Teixeira CS; Malachias A; Magalhães-Paniago R; de Souza Filho JD; Oliveira BL; Guimarães AR; Caravan P; Ferreira LA; Alves RJ; Oliveira MC
    Int J Nanomedicine; 2016; 11():3737-51. PubMed ID: 27563241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of lipid composition on the ability of liposome loaded voacamine to improve the reversion of doxorubicin resistant osteosarcoma cells.
    Giansanti L; Condello M; Altieri B; Galantini L; Meschini S; Mancini G
    Chem Phys Lipids; 2019 Sep; 223():104781. PubMed ID: 31229409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CB65 and novel CB65 liposomal system suppress MG63 and Saos-2 osteosarcoma cell growth
    Zorba BI; Boyacıoğlu Ö; Çağlayan T; Reçber T; Nemutlu E; Eroğlu İ; Korkusuz P
    J Liposome Res; 2024 Jun; 34(2):274-287. PubMed ID: 37740901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aptamer-based liposomes improve specific drug loading and release.
    Plourde K; Derbali RM; Desrosiers A; Dubath C; Vallée-Bélisle A; Leblond J
    J Control Release; 2017 Apr; 251():82-91. PubMed ID: 28238787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A liposomal formulation of doxorubicin, composed of hexadecylphosphocholine (HePC): physicochemical characterization and cytotoxic activity against human cancer cell lines.
    Papagiannaros A; Hatziantoniou S; Dimas K; Papaioannou GT; Demetzos C
    Biomed Pharmacother; 2006 Jan; 60(1):36-42. PubMed ID: 16271845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of antiproliferative long-circulating liposomes co-encapsulating doxorubicin and curcumin, through the use of a quality-by-design approach.
    Tefas LR; Sylvester B; Tomuta I; Sesarman A; Licarete E; Banciu M; Porfire A
    Drug Des Devel Ther; 2017; 11():1605-1621. PubMed ID: 28579758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new formulation of hydrophobin-coated niosome as a drug carrier to cancer cells.
    Barani M; Mirzaei M; Torkzadeh-Mahani M; Lohrasbi-Nejad A; Nematollahi MH
    Mater Sci Eng C Mater Biol Appl; 2020 Aug; 113():110975. PubMed ID: 32487392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomal Doxorubicin Delivery Systems: Effects of Formulation and Processing Parameters on Drug Loading and Release Behavior.
    Mohammadi ZA; Aghamiri SF; Zarrabi A; Talaie MR
    Curr Drug Deliv; 2016; 13(7):1065-1070. PubMed ID: 26708673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Smart thermo/pH responsive magnetic nanogels for the simultaneous delivery of doxorubicin and methotrexate.
    Salehi R; Rasouli S; Hamishehkar H
    Int J Pharm; 2015 Jun; 487(1-2):274-84. PubMed ID: 25895723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxidized phospholipid based pH sensitive micelles for delivery of anthracyclines to resistant leukemia cells in vitro.
    Wang Y; Chen L; Ding Y; Yan W
    Int J Pharm; 2012 Jan; 422(1-2):409-17. PubMed ID: 22037443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted temperature sensitive magnetic liposomes for thermo-chemotherapy.
    Pradhan P; Giri J; Rieken F; Koch C; Mykhaylyk O; Döblinger M; Banerjee R; Bahadur D; Plank C
    J Control Release; 2010 Feb; 142(1):108-21. PubMed ID: 19819275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The liposomal formulation of doxorubicin.
    Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
    Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formulation kit for liposomal doxorubicin composed of lyophilized liposomes.
    Stevens PJ; Lee RJ
    Anticancer Res; 2003; 23(1A):439-42. PubMed ID: 12680245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of vitamin loaded topical liposomal formulation using factorial design approach: drug deposition and stability.
    Padamwar MN; Pokharkar VB
    Int J Pharm; 2006 Aug; 320(1-2):37-44. PubMed ID: 16707237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and evaluation of pH-sensitive liposomes constructed by poly(2-ethyl-2-oxazoline)-cholesterol hemisuccinate for doxorubicin delivery.
    Xu H; Hu M; Yu X; Li Y; Fu Y; Zhou X; Zhang D; Li J
    Eur J Pharm Biopharm; 2015 Apr; 91():66-74. PubMed ID: 25660909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.